

Coala Life enters into a convertible loan facility of SEK 25 M with existing shareholders

Coala-Life Group AB (publ) ("Coala Life" or "The Company") has entered into a loan facility agreement of SEK 25 M with a consortium of existing shareholder, to ensure that the Company has sufficient funds to meet the short-term working capital needs. The facility is available to the Company, to be utilized in its entirety, until March 31, 2023, and matures December 31, 2023.

The Company has entered into a loan facility agreement today, November 15, 2022, with a consortium of existing shareholders. The loan facility amounts to SEK 25 M, and can only be utilized in its entirety, should the Company require the funds to meet its working capital needs. The loan facility can be utilized until March 31, 2023, with an annual interest rate of eight (8) percent, starting from the utilization date. The utilized amount can be converted in a future share issue, to the same terms as offered to other investors, alternatively repaid to the lenders in cash in its entirety, no later than the maturity date December 31, 2023. The Company's and the lenders' mutual intention is to have the utilized amount converted into shares.

"It is very encouraging that our large shareholders are willing to participate in the convertible loan facility, that can be converted into shares. It proves that our owners believe in our long-term growth plans in the American market", says Dan Pitulia, CEO of Coala- Life Group AB.

For more information, please contact:

Dan Pitulia, CEO Coala Life AB
+46 70 972 08 38, dan.pitulia@coalalife.com
Richard Roa, CFO Coala Life AB
+46 70 816 61 45, richard.roa@coalalife.com

Certified Adviser
The company's Certified Adviser is Erik Penser Bank AB.

About us

Coala-Life Group AB ("Coala Life" or the "Company") founded in 2015, is a Cloud Based Software as a Service provider, and medical device developer and reseller, listed on Nasdaq First North Growth Market. The Company focuses on B2B solutions for managed Remote Patient Monitoring ("RPM"), offering medical care providers, primarily in the US, with a highly scalable, cost-efficient platform to remotely and virtually manage large volumes of patients suffering from chronic diseases. The company offers care providers a comprehensive solution and lifts the administrative work from the care providers regarding, amongst other things, follow-up, 24/7 monitoring, as well as the reimbursement process from state and private health insurance companies. Patients are monitored long-term in everyday life and typically have diabetes, obesity, and /or cardiovascular disease.

For more information see www.coalalife.com

This information is information that Coala Life is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-15 21:00 CET.

Attachments

[Coala Life enters into a convertible loan facility of SEK 25 M with existing shareholders](#)